Life sciences AI for every team that writes, reviews, and approves
One platform for every team
From nonclinical summaries and clinical study reports to safety reports, health authority responses, and manuscripts, see how Artos puts your team’s knowledge to work across critical workflows.
AI for nonclinical writing
Documents: Nonclinical overviews and summaries (Module 2.4 and 2.6) · Toxicology and pharmacology reports
Turn study reports and tabulated data into nonclinical summaries that stay aligned with their sources, from toxicology and pharmacology findings to the IND.
✓
Nonclinical written and tabulated summaries drafted from your study reports
✓
Every value traced back to the study it came from
AI for CMC authoring
Documents: Module 3 quality sections · CMC content for INDs, NDAs, and BLAs
Keep Module 3 aligned with current specifications, methods, and batch data. See where changes have an impact and draft updates across affected sections and regions.
✓
3.2.S and 3.2.P sections drafted from your source data
✓
See every section and region a change affects before review
AI for safety reporting
Documents: DSURs · PSURs and PBRERs · Safety narratives
Draft aggregate safety reports from your latest data, with every number checked against its source and the same safety language from one reporting period to the next.
✓
DSURs, PSURs, and PBRERs drafted from your safety data
✓
Consistent safety messaging across reports and periods
AI for regulatory affairs
Documents: INDs, NDAs, BLAs, and CTD modules, with eCTD-ready output · Briefing books · Labeling
Trace claims back to their sources, respond to health authority questions, and see how changes in FDA, EMA, or ICH guidance affect your programs.
✓
Briefing books and health authority query responses drafted from the same data as the dossier
✓
Labeling kept consistent with your latest data and guidance
AI for medical communications
Documents: Manuscripts · Publications
Draft publications and manuscripts from the same approved data as your clinical documents, so results and claims match across what you submit and what you publish.
✓
Manuscripts drafted from your study data and approved content
✓
The same results and messaging across publications and regulatory documents
By organization
How Artos fits your organization
Our team has done this work at Bristol Myers Squibb, Parexel, IQVIA, and Verily, so we know what each kind of organization is up against.
How customers use Artos
Which other teams use the platform?
Clinical, quality, and medical affairs teams use it too, along with the reviewers and leaders who sign off on the work.
Does Artos work with large pharma, biotech, and CROs?
Yes. Large pharma teams get enterprise governance, permissions, and integrations. Biotechs take on more critical work with the team they have. CROs and CDMOs work in each sponsor’s templates and keep each sponsor’s data separate, while reusing their own methods and agents.
Can different teams in the same organization use the platform differently?
Yes. Medical writing, nonclinical, CMC, safety, regulatory, and medical communications teams each get document types and workflows suited to their work, all built on the same source data. When one team updates a value, agents draft the change in every document that uses it, across teams.
Do our writers need technical or AI skills?
No. People keep working in the systems they already use, and inside the platform they work in familiar views: a document, a review pane, or a chat box. There’s no prompt engineering to learn and no data team needed.
How do reviewers and QA teams use the platform?
Reviewers can trace every sentence to its source and see the agent’s reasoning. QA teams use the Checklist agent to check documents against SOPs and quality requirements, while the QC agent verifies data points against their sources.
Can our data team use the structured data directly?
Yes. The schema is open and documented, so teams can build their own pipelines to move data into and out of the Artos platform for big data projects, analytics dashboards, customizations, and more.